Trial Search Results
Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors
The purpose of this clinical trial is to demonstrate that wavefront-guided LASIK is safe and effective for the correction of myopic refractive errors.
Stanford is currently not accepting patients for this trial.
Abbott Medical Optics
- Device: LASIK correction of myopic refractive errors
- 18 years of age or greater
- Best Spectacle Corrected Visual Acuity (BSCVA) of 20/20 or better
- Uncorrected visual acuity (UCVA) of 20/40 or worse
- Less than 0.75D difference between cycloplegic and manifest refraction sphere.
- Demonstration of refractive stability
- Anticipated post-operative stromal bed thickness of at least 250 microns
- Willing and capable of returning for follow-up examinations for the duration of the
- Women who are pregnant, breast-feeding, or intend to become pregnant over the course
of the study
- Concurrent use of topical or systemic medications that may impair healing
- History of any medical conditions that could affect wound healing
- History of prior intraocular or corneal surgery, active ophthalmic disease, or other
- Evidence of keratoconus, corneal irregularity, or abnormal topography in the operative
- Known sensitivity or inappropriate responsiveness to any of the medications used in
the post-operative course
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study